Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) PT at $32.33

Shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) have received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.3333.

A number of analysts recently commented on OKUR shares. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of OnKure Therapeutics in a research note on Tuesday, August 26th. Zacks Research lowered OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th.

Hedge Funds Weigh In On OnKure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Advisers LP acquired a new position in OnKure Therapeutics during the 4th quarter worth approximately $122,000. Bank of America Corp DE purchased a new stake in OnKure Therapeutics during the 4th quarter worth approximately $2,147,000. Millennium Management LLC purchased a new stake in OnKure Therapeutics during the 4th quarter worth approximately $1,239,000. Northern Trust Corp purchased a new stake in OnKure Therapeutics during the 4th quarter worth approximately $165,000. Finally, Affinity Asset Advisors LLC increased its holdings in OnKure Therapeutics by 173.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 394,159 shares of the company’s stock worth $1,695,000 after purchasing an additional 250,000 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

OnKure Therapeutics Stock Down 2.4%

OKUR opened at $2.39 on Friday. The firm has a market cap of $32.34 million, a P/E ratio of -0.50 and a beta of 0.42. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $20.00. The business’s fifty day simple moving average is $2.47 and its 200 day simple moving average is $2.89.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.09. As a group, equities analysts expect that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.